Immune Effector Cell-Associated Neurotoxicity Syndrome Related to Chimeric Antigen Receptor T-Cell Therapy | Neurology
An 18-year-old woman with a refractory large B-cell lymphoma stage III (without CNS involvement) was admitted for the administration of anti-CD19 CAR-T therapy. On the third day, she developed severe cytokine-release syndrome (CRS). Treatment with tocilizumab (3 weight-adjusted doses), dexamethasone (40 mg/6 h), levetiracetam (1,500 mg/12 h), and anakinra (100 mg/6 h) 1 was started, requiring orotracheal intubation (OTI). She was extubated on the ninth day but presented confusion and inattention compatible